<?xml version="1.0"?>

<document>
	<title>Autoantibodies in serum and sputum from patients with cystic
   fibrosis.</title>

	<author>Schiotz-P-O.</author>
	<author>Egeskjold-E-M.</author>
	<author>Hoiby-N.</author>
	<author>Permin-H.</author>

	<source>Acta-Pathol-Microbiol-Scand [C]. 1979 Oct. 87(5). P 319-24.</source>

	<abstract>Sera from 89 patients with cystic fibrosis (CF) and 88 control
   persons were examined for the occurrence of rheumatoid factors (RF)
   of the IgG, IgA and IgM classes by an indirect immunofluorescence
   method and by the latex fixation slide test. The prevalence of RF-IgG
   was significantly higher (88%) (p less than 0.0005) among the CF
   patients than among the control persons (7%), while no difference was
   found between the two groups with regard to RF of the IgA or IgM
   classes. Fifty-five of the CF patients had chronic Pseudomonas
   aeruginosa infection in their lungs and two or more precipitins
   against these bacteria in their sera determined by crossed
   immunoelectrophoresis. These CF patients did not differ from the 34
   CF patients without chronic P. aeruginosa infection, neither with
   regard to prevalence nor titer of RFs, but there was a positive
   correlation between the number of P. aeruginosa precipitins in the 55
   chronically infected CF patients and their titers of IgG-RF. Nineteen
   CF patients were examined also for RFs, antinuclear antibodies (ANA)
   and anti-DNA antibodies in their sputum sol phase and corresponding
   sera. RFs were demonstrated in the sputum sol phase from 6 of the
   patients by the latex fixation test, whereas their sera were negative
   in this test, possibly indicating a local production of RF. Positive
   reactions for ANA and anti-DNA antibodies were found in 7 and 10 of
   the sputa respectively, and in higher titers than in the
   corresponding sera, also suggesting a local production. Titers of
   autoantibodies in sputum were low and no difference was found between
   patients with chronic P. aeruginosa infection and patients without P.
   aeruginosa infection. The possible role of autoantibodies in the
   patogenesis of pulmonary tissue damage in CF patients is discussed.</abstract>

	<majorsubject>AUTOANTIBODIES: an</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: im</majorsubject>
	<majorsubject>SPUTUM: im</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>ADULT</minorsubject>
	<minorsubject>ANTINUCLEAR-FACTORS: an</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CHILD-PRESCHOOL</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: co</minorsubject>
	<minorsubject>DNA: im</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>FLUORESCENT-ANTIBODY-TECHNIC</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>IGA: an</minorsubject>
	<minorsubject>IGG: an</minorsubject>
	<minorsubject>IGM: an</minorsubject>
	<minorsubject>IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL</minorsubject>
	<minorsubject>LATEX-FIXATION-TESTS</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>PSEUDOMONAS-AERUGINOSA</minorsubject>
	<minorsubject>PSEUDOMONAS-INFECTIONS: co, im</minorsubject>
	<minorsubject>RHEUMATOID-FACTOR: an</minorsubject>

	<reference>001   BARTFELD H            ANN NY ACAD SCI                168    30 969</reference>
	<reference>002   BONOMO L              AM J CLIN PATHOL                45   313 966</reference>
	<reference>003   BROGAN TD             THORAX                          30    72 975</reference>
	<reference>004   CARSON DA             CLIN EXP IMMUNOL                31   100 978</reference>
	<reference>005   DEHORATIUS RJ         ARCH INTERN MED                129   441 972</reference>
	<reference>006   DEHORATIUS RJ         ARTHRITIS RHEUM                 15   293 972</reference>
	<reference>007   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962</reference>
	<reference>008   ESTES D               ARTHRITIS RHEUM                 16    59 973</reference>
	<reference>009   GIBSON LE             PEDIATRICS                      23   545 959</reference>
	<reference>010   HODSON ME             BR J DIS CHEST                  70    83 976</reference>
	<reference>011   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973</reference>
	<reference>012   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974</reference>
	<reference>013   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974</reference>
	<reference>014   HOIBY N               SCAND J RESPIR DIS              56    38 975</reference>
	<reference>015   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977</reference>
	<reference>016   HOIBY N               SCAND J RESPIR DIS              58    65 977</reference>
	<reference>017   KALLERUP HE           SCAND J RHEUMATOL                8     1 979</reference>
	<reference>018   KOFFLER D             J EXP MED                      126   607 967</reference>
	<reference>019   KOFFLER D             J EXP MED                      134   169 971</reference>
	<reference>020   LIEBERMAN J           LAB INVEST                      14   249 965</reference>
	<reference>021   LIND I                SCAND J IMMUNOL                  3   689 974</reference>
	<reference>022   MCCORMICK JN          IN: DUMONDE D                         68 976</reference>
	<reference>023   MCFARLANE H           BR MED J                         1   423 975</reference>
	<reference>024   MUNTHE E              CLIN EXP IMMUNOL                 8   249 971</reference>
	<reference>025   PERMIN H              ACTA MED SCAND                 203    61 978</reference>
	<reference>026   RHEINS MS             J LAB CLIN MED                  50   113 957</reference>
	<reference>027   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975</reference>
	<reference>028   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977</reference>
	<reference>029   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978</reference>
	<reference>030   TAN EM                J CLIN INVEST                   45  1732 966</reference>
	<reference>032   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974</reference>
	<reference>033   TURNER-WARWICK M      BR MED J                         3   492 970</reference>
	<reference>034   WALLER M              J INFECT DIS                   125    45 972</reference>
	<reference>035   WIIK A                IMMUNOLOGY                      23    53 972</reference>
	<reference>036   WIIK A                ANN RHEUM DIS                   33   515 974</reference>
	<reference>037   WINCHESTER RJ         CLIN EXP IMMUNOL                 6   689 970</reference>

	<citation>1   EGESKJOLD EM          ALLERGY                         36   573 981</citation>
	<citation>2   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981</citation>
	<citation>3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982</citation>
	<citation>4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982</citation>
	<citation>5   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985</citation>
	<citation>6   EGESKJOLD EM          SCAND J RHEUMATOL               14    51 985</citation>
	<citation>7   DISIS ML              PEDIATR RES                     20   385 986</citation>
	<citation>8   LIMSCHOU EME          DAN MED BULL                    33   249 986</citation>
	<citation>9   HOIBY N               ANNU REV MICROBIOL              40    29 986</citation>

</document>
